Robeco Institutional Asset Management B.V. Increases Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Robeco Institutional Asset Management B.V. lifted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Rating) by 21.7% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 89,507 shares of the medical equipment provider’s stock after buying an additional 15,965 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Zimmer Biomet were worth $9,355,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of ZBH. Guardian Wealth Advisors LLC purchased a new position in Zimmer Biomet in the third quarter valued at approximately $28,000. Ronald Blue Trust Inc. purchased a new position in Zimmer Biomet in the second quarter valued at approximately $37,000. Western Pacific Wealth Management LP purchased a new position in Zimmer Biomet in the third quarter valued at approximately $44,000. Tsfg LLC lifted its stake in Zimmer Biomet by 295.5% in the third quarter. Tsfg LLC now owns 435 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 325 shares during the last quarter. Finally, Allworth Financial LP lifted its stake in Zimmer Biomet by 46.9% in the third quarter. Allworth Financial LP now owns 457 shares of the medical equipment provider’s stock valued at $48,000 after purchasing an additional 146 shares during the last quarter. Hedge funds and other institutional investors own 87.21% of the company’s stock.

Zimmer Biomet Trading Down 0.9 %

Zimmer Biomet stock opened at $124.31 on Friday. The stock has a market cap of $26.11 billion, a P/E ratio of 113.01, a PEG ratio of 2.87 and a beta of 1.00. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.97 and a current ratio of 1.88. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $100.39 and a fifty-two week high of $135.05. The firm’s fifty day moving average price is $125.21 and its 200-day moving average price is $118.70.

Zimmer Biomet (NYSE:ZBH – Get Rating) last released its earnings results on Friday, February 3rd. The medical equipment provider reported $1.88 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.05. The business had revenue of $1.83 billion for the quarter, compared to analysts’ expectations of $1.76 billion. Zimmer Biomet had a return on equity of 11.97% and a net margin of 3.33%. The firm’s revenue was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.95 earnings per share. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.04 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 28th. Shareholders of record on Wednesday, March 29th will be given a dividend of $0.24 per share. The ex-dividend date is Tuesday, March 28th. This represents a $0.96 annualized dividend and a yield of 0.77%. Zimmer Biomet’s payout ratio is 87.27%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Piper Sandler upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $135.00 to $145.00 in a research note on Thursday, March 9th. Robert W. Baird boosted their target price on shares of Zimmer Biomet from $133.00 to $145.00 in a report on Monday, February 6th. Truist Financial boosted their target price on shares of Zimmer Biomet from $135.00 to $137.00 and gave the company a “hold” rating in a report on Monday, February 6th. Wells Fargo & Company raised shares of Zimmer Biomet from an “underweight” rating to an “equal weight” rating and boosted their target price for the company from $116.00 to $124.00 in a report on Wednesday, November 23rd. Finally, Morgan Stanley boosted their target price on shares of Zimmer Biomet from $135.00 to $140.00 and gave the company an “equal weight” rating in a report on Monday, February 6th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average target price of $133.56.

Zimmer Biomet Company Profile

(Get Rating)

Zimmer Biomet Holdings, Inc engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products.